NetworkNewsBreaks – IsoRay, Inc. (NYSE: ISR) Initiates Pilot Study for Cesium-131 Impact on Head and Neck Cancer
Leading medical technology company IsoRay (NYSE: ISR) recently launched a new study to analyze the impact and safety of Cesium-131 brachytherapy seeds on recurrent neck and head cancer. The pilot study will be conducted at the Cleveland, Ohio, Case Western Reserve University’s Case Comprehensive Cancer Center, and it will begin enrollment of 42 subjects in early 2017. It is estimated that there are approximately 61,760 cases of neck and head cancer currently diagnosed in the United States. In case of recurrence, which happens with 30-40% of the cases, radiation therapy might not always be possible given the presence of vital…







